Prior to joining WPI, Dr. Soboyejo was a Professor in Mechanical and Aerospace Engineering at Princeton University for approximately 17 years. He is a materials scientist whose research focuses on biomaterials and the use of nanoparticles for the detection and treatment of disease, the mechanical properties of materials, and the use of materials science to promote global development. His current projects include the use of nanomaterials for targeting and treating cancer; a shear assay technique that may be able to measure the mechanical properties of organelles in the cell; the development of low cost solar cells/light emitting devices; and sustainable approaches to providing clean water, affordable housing and education to people in the developing world. Dr. Soboyejo brings to WPI an exceptional record of achievement in engineering research and academic leadership, as well as impressive accomplishments in international development and a noteworthy track record in building global research and educational partnerships. For example, he founded the U.S./Africa Materials Institute at Princeton, one of six international materials institutes supported by the National Science Foundation. He has also served as President and Provost of the African University of Science and Technology (AUST) in Abuja, Nigeria, a Pan-African university founded by the Nelson Mandela Institutions (NMI). Dr. Soboyejo has also served as the chair of the African Scientific Committee of the NMI. He held research positions at the McDonnell Douglas Research Laboratories in St. Louis and the Edison Welding Institute in Columbus, Ohio, as well as faculty positions at The Ohio State University and MIT, before joining the Princeton faculty in 1999.
More than 70 media outlets, including the Latin Trade , Pittsburgh Post Gazette, and the Oklahoman carried the news of WPI welcoming 19 full-time educators and researchers to its faculty for the 2020-21 academic year.
Provost Wole Soboyejo appeared on Spectrum News 1 discussing his research in identifying targeted drugs that reduced the sizes of hard-to-treat breast cancer tumors in mice without inducing the toxic side effects that are typically associated with conventional chemotherapy.